» Articles » PMID: 34718931

Isavuconazole and Liposomal Amphotericin B As Successful Combination Therapy of Refractory Invasive Candidiasis in a Liver Transplant Recipient: A Case Report and Literature Review

Overview
Journal Mycopathologia
Date 2021 Oct 31
PMID 34718931
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Invasive fungal infections in liver transplant recipients are associated with elevated morbidity and mortality and pose a challenge to the treating physicians. Despite of lacking clinical data, the use of antifungal combination therapy is often considered to improve response rates in an immunocompromised patient population. We herein report a case of refractory invasive candidiasis in a liver transplant recipient treated successfully with a combination of isavuconazole und high-dose liposomal amphotericin B. The antimycotic combination treatment was able to clear a bloodstream infection with C. glabrata and led to regression of bilomas among tolerable side effects. The use of the above-mentioned antifungal combination therapy in a liver transplant recipient has not been reported previously. This case highlights the efficacy and safety of antifungal combination therapy in immunocompromised patients with refractory invasive candidiasis.

Citing Articles

Case report: Successful combination therapy with isavuconazole and amphotericin B in treatment of disseminated infection.

Teng Q, Ye X, Wang B, Zhang X, Tao Z, Yin X Front Med (Lausanne). 2024; 11:1397539.

PMID: 38978781 PMC: 11228301. DOI: 10.3389/fmed.2024.1397539.


Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.

Zhang T, Shen Y, Feng S Front Cell Infect Microbiol. 2022; 12:1049959.

PMID: 36530445 PMC: 9751058. DOI: 10.3389/fcimb.2022.1049959.


Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications.

Haro-Reyes T, Diaz-Peralta L, Galvan-Hernandez A, Rodriguez-Lopez A, Rodriguez-Fragoso L, Ortega-Blake I Membranes (Basel). 2022; 12(7).

PMID: 35877884 PMC: 9316096. DOI: 10.3390/membranes12070681.


Antifungal Resistance and the Role of New Therapeutic Agents.

Logan A, Wolfe A, Williamson J Curr Infect Dis Rep. 2022; 24(9):105-116.

PMID: 35812838 PMC: 9255453. DOI: 10.1007/s11908-022-00782-5.

References
1.
Moen M, Lyseng-Williamson K, Scott L . Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009; 69(3):361-92. DOI: 10.2165/00003495-200969030-00010. View

2.
Nishi I, Sunada A, Toyokawa M, Asari S, Iwatani Y . In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species. J Infect Chemother. 2009; 15(1):1-5. DOI: 10.1007/s10156-008-0653-9. View

3.
Pappas P, Lionakis M, Arendrup M, Ostrosky-Zeichner L, Kullberg B . Invasive candidiasis. Nat Rev Dis Primers. 2018; 4:18026. DOI: 10.1038/nrdp.2018.26. View

4.
Pomorska A, Malecka A, Jaworski R, Radon-Proskura J, Hare R, Nielsen H . Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature. Mycopathologia. 2018; 184(1):81-88. DOI: 10.1007/s11046-018-0287-0. View

5.
Katragkou A, McCarthy M, Meletiadis J, Hussain K, Moradi P, Strauss G . In vitro combination therapy with isavuconazole against Candida spp. Med Mycol. 2017; 55(8):859-868. DOI: 10.1093/mmy/myx006. View